BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND ABL1, p150, 25, ENSG00000097007, P00519, v-abl, bcr/abl, JTK7, c-ABL, ABL, BCR-ABL AND Clinical Outcome
100 results:

  • 1. Long Non-Coding RNAs: Bridging cancer-Associated Thrombosis and clinical outcome of ovarian cancer Patients.
    Marques IS; Tavares V; Savva-Bordalo J; Rei M; Liz-Pimenta J; de Melo IG; Assis J; Pereira D; Medeiros R
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203310
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
    Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
    Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
    Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
    BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Isolated lymph node recurrence in epithelial ovarian cancer - management and outcome.
    Jain V; Debnath S; Sharma A; Kamboj M; Mohanty A; Rawal S
    J Visc Surg; 2023 Jun; 160(3):169-179. PubMed ID: 36564260
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts.
    Konaté MM; Li MC; McShane LM; Zhao Y
    Sci Rep; 2022 Nov; 12(1):19283. PubMed ID: 36369472
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Characteristics associated with inflammatory breast cancer (IBC): An epidemiologic study from a dedicated IBC program.
    White RE; Warren L; Nakhlis F; Rosenbluth J; Bellon J; Block C; Overmoyer B
    Breast J; 2020 Sep; 26(9):1688-1694. PubMed ID: 32875655
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
    Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Prediction of in vitro fertilization outcome at different antral follicle count thresholds combined with female age, female cause of infertility, and ovarian response in a prospective cohort of 8269 women.
    Liao S; Xiong J; Tu H; Hu C; Pan W; Geng Y; Pan W; Lu T; Jin L
    Medicine (Baltimore); 2019 Oct; 98(41):e17470. PubMed ID: 31593108
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Germline
    de Jonge MM; Ritterhouse LL; de Kroon CD; Vreeswijk MPG; Segal JP; Puranik R; Hollema H; Rookus MA; van Asperen CJ; van Leeuwen FE; Smit VTHBM; Howitt BE; Bosse T;
    Clin Cancer Res; 2019 Dec; 25(24):7517-7526. PubMed ID: 31492746
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables.
    Gadducci A; Guerrieri ME; Cosio S
    Crit Rev Oncol Hematol; 2019 Mar; 135():103-114. PubMed ID: 30819439
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Intraperitoneal α-Emitting Radioimmunotherapy with
    Hallqvist A; Bergmark K; Bäck T; Andersson H; Dahm-Kähler P; Johansson M; Lindegren S; Jensen H; Jacobsson L; Hultborn R; Palm S; Albertsson P
    J Nucl Med; 2019 Aug; 60(8):1073-1079. PubMed ID: 30683761
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
    Timmermans M; van der Aa MA; Lalisang RI; Witteveen PO; Van de Vijver KK; Kruitwagen RF; Sonke GS
    Gynecol Oncol; 2018 Sep; 150(3):446-450. PubMed ID: 30001834
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological cancers.
    Nielsen B; Kleppe A; Hveem TS; Pradhan M; Syvertsen RA; Nesheim JA; Kristensen GB; Trovik J; Kerr DJ; Albregtsen F; Danielsen HE
    J Natl Cancer Inst; 2018 Dec; 110(12):1400-1408. PubMed ID: 29684152
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. p53-Reactive T Cells Are Associated with clinical Benefit in Patients with Platinum-Resistant Epithelial ovarian cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
    Hardwick NR; Frankel P; Ruel C; Kilpatrick J; Tsai W; Kos F; Kaltcheva T; Leong L; Morgan R; Chung V; Tinsley R; Eng M; Wilczynski S; Ellenhorn JDI; Diamond DJ; Cristea M
    Clin Cancer Res; 2018 Mar; 24(6):1315-1325. PubMed ID: 29301826
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
    Hollis RL; Meynert AM; Churchman M; Rye T; Mackean M; Nussey F; Arends MJ; Sims AH; Semple CA; Herrington CS; Gourley C
    BMC Cancer; 2018 Jan; 18(1):16. PubMed ID: 29298688
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.
    Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG
    Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance.
    Krishna Priya S; Kumar K; Hiran KR; Bindhu MR; Nagare RP; Vijaykumar DK; Ganesan TS
    Int J Clin Oncol; 2017 Feb; 22(1):107-117. PubMed ID: 27567920
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Vacuum-assisted breast biopsies (VAB) carried out on an open 1.0T MR imager: Influence of patient and target characteristics on the procedural and clinical results.
    Krug B; Hellmich M; Ulhaas A; Krämer S; Rhiem K; Zarghooni V; Püsken M; Schwabe H; Grinstein O; Markiefka B; Maintz D
    Eur J Radiol; 2016 Jun; 85(6):1157-66. PubMed ID: 27161066
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Cell proliferation, measured as flow cytometric S-phase fraction, is a strong prognostic indicator in FIGO stage I endometrioid endometrial carcinoma: a population-based study.
    Green RW; Engblom S; Baldetorp B; Hartman L; Måsbäck A; Bjurberg M
    Acta Obstet Gynecol Scand; 2015 Oct; 94(10):1064-73. PubMed ID: 26123703
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.